Last updated on December 2018

Exercise to Reduce Chemotherapy-Induced Peripheral Neuropathy

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions: Colorectal Cancer
  • Age: Between 18 - 100 Years
  • Gender: Male or Female

Inclusion Criteria:

  • Diagnosed GI cancer (e.g, colorectal, gastric, pancreatic, esophageal, bowel);
  • Scheduled to receive at least 6 cycles of oxaliplatin (85 mg/m2);
  • Receiving care at the University of Michigan or St. Joseph Cancer Clinics;
  • A Karnofsky Performance Status 80% or an Eastern Cooperative Oncology Group Status 0 to 1;
  • Voluntarily consented to participate in all intervention components.

Exclusion Criteria:

  • Exercise- or mobility-limiting cardiovascular, pulmonary, musculoskeletal, or psychological disease, based on the EMR (electronic medical record) past medical history and consultation with the medical oncologist;
  • Scheduled major surgery during the study time period;
  • Pre-existing peripheral neuropathy prior to chemotherapy (potentially due to diabetes, central nervous system malignancy, vitamin deficiency, heredity, nerve compression injury, non-surgically corrected carpal tunnel disease, or alcohol dependence) per patient self-report in response to brief screening questions noted in the pre-screening section;
  • Prior receipt of neurotoxic chemotherapy - taxanes (paclitaxel and docetaxel), platinums (cisplatin, oxaliplatin, and carboplatin), vinca alkaloids (vincristine and vinblastine), proteasome inhibitors (bortezomib), and thalidomide;
  • Pregnancy;
  • Inability to read or speak English;
  • Prognosis of less than three months.

Recruitment Status: Open

Brief Description Eligibility Contact Research Team

Volunteer Sign-up

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.